Inside the GLP-1 Study for Long COVID, with lead scientist Dr Julia Vogel, Long Covid, MD Pod, Ep 61

Dr Khan interviews Dr. Julia Moore-Vogel, Scripps Researcher and one of the Principal Investigators on the LoCITT-T study. The study uses tirzepatide to treat moderate to severe long Covid, and is actively enrolling participants. Watch to learn all the important details: the study's design, eligibility criteria, and the potential benefits of the drug. Dr Vogel shares her personal experience with long COVID and how it has influenced her work. The conversation also covers the importance of making clinical trials accessible to those with disabilities and the innovative use of wearable technology in the study.

Resources:
Long COVID Treatment Trial-Tirzepatide (LoCITT-T): https://www.longcovid.scripps.edu

Fatigue Severity Scale: https://www.med.upenn.edu/cbti/assets...

FUN-CAP 27: https://batemanhornecenter.org/wp-con...

DSQ-COVID: https://www.researchgate.net/publicat...

Eric Topol, MD Ground Truths: https://erictopol.substack.com/

All of Us Research Hub: https://www.researchallofus.org/

Chapters
00:00 Introduction to Julia Moore Vogel and Her Work
01:28 Why GLP Drugs Could Work
04:13 The LoCCIT-T Study
07:18 Study Design and Participant Enrollment Process
10:03 Participant Experience and Support
12:51 Join the Community!
13:40 Study Duration and Data Analysis
16:44 Dosing Strategies and Safety Considerations
22:17 Personal Journey with Long COVID
30:58 Decentralized Study Design and Accessibility
36:26 How to Enroll
38:16 Outro